Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, which took place from June 12-15, 2026, in Istanbul, Turkey.

"The data presented at EAACI continue to provide evidence supporting a potentially differentiated profile of deucrictibant in both the on-demand setting and the prophylactic setting," said Berndt Modig, Chief Executive Officer of Pharvaris. "Pharvaris' commitment to developing therapies that can meaningfully improve standard of care remains at the forefront of our work. We were pleased to be amongst those who contributed to the AURORA international consensus and are proud to have sponsored the first-ever on-demand HAE clinical study that assessed EoP as a prespecified efficacy endpoint."

Peng Lu, M.D., Ph.D., President of Pharvaris, added, "The compelling topline efficacy data from RAPIDe-3, combined with the high proportion of attacks treated with a single capsule of deucrictibant, underscore the potential for deucrictibant to address unmet needs in the on-demand treatment setting. Additionally, in the prophylactic treatment setting, deucrictibant's rapid and durable prevention of HAE attacks, well-tolerated profile, and sustained improvement in disease control and HRQoL reflect the potential for its broader positive impact as an effective and well-tolerated prophylactic treatment for HAE attacks."